Characterization of Diarrhea Adverse Events with Nerandomilast in Patients with Autoimmune Interstitial Lung Disease and Progressive Pulmonary Fibrosis in the FIBRONEER-ILD Trial (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1774; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Cyclophosphamide, tocilizumab, mycophenolate, rituximab, and prednisone >15 mg/day (or equivalent) were not permitted at enrolment, but could be initiated after 6 months to manage worsening of systemic disease...Methotrexate and azathioprine were the most frequently used immunomodulatory medications, taken by 11.7% and 10.8% of patients, respectively...The proportions of patients with diarrhea adverse events in the placebo, nerandomilast 9 mg bid and nerandomilast 18 mg bid groups, respectively, were 19.7%, 19.2% and 22.9% in patients not taking nintedanib and 34.5%, 46.2% and 44.2% in patients taking nintedanib... The majority of patients with autoimmune ILDs and PPF treated with nerandomilast in the FIBRONEER-ILD trial did not have diarrhea adverse events. Most patients who had diarrhea had only one event. Most diarrhea events were mild or moderate in severity."
Adverse events • Clinical • Idiopathic Pulmonary Fibrosis • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Scleroderma • Systemic Sclerosis
|
|
Anna-Maria Hoffmann-Vold1; Shervin Assassi2; Lorinda Chung3; Masashi Bando4; Brian Jonat5; Patrick Hofmann6; Daniel Wachtlin7; Gerrit Weimann6; Michael Kreuter8
|